MDL-28170

MDL-28170 (Calpain Inhibitor III) is a potent, selective and membrane-permeable cysteine protease inhibitor of calpain that rapidly penetrates the blood-brain barrier following systemic administration[1][2]. MDL-28170 also block γ-secretase[4].

Product Specifications

CAS Number

[88191-84-8]

Product Name Alternative

Calpain Inhibitor III

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Proteasome

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/MDL-28170.html

Concentration

10mM

Purity

97.0

Solubility

DMSO : 30 mg/mL (ultrasonic; warming)

Smiles

O=C(N[C@@H](C(C)C)C(NC(CC1=CC=CC=C1)C=O)=O)OCC2=CC=CC=C2

Molecular Formula

C22H26N2O4

Molecular Weight

382.45

Precautions

H302, H315, H319, H335

References & Citations

[1]Chen ZF, et al. Neuronal recovery after moderate hypoxia is improved by the calpain inhibitor MDL28170. Brain Res. 1997 Sep 19;769 (1) :188-92.|[2]Li PA, et al. Postischemic treatment with calpain inhibitor MDL 28170 ameliorates brain damage in a gerbil model of global ischemia. Neurosci Lett. 1998 May 8;247 (1) :17-20.|[3]Ai J, et al. Calpain inhibitor MDL-28170 reduces the functional and structural deterioration of corpus callosum following fluid percussion injury. J Neurotrauma. 2007 Jun;24 (6) :960-78.|[4]De Strooper B, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999 Apr 8;398 (6727) :518-22.|[5]Kharatmal SB, et al. Calpain inhibitor, MDL 28170 confer electrophysiological, nociceptive and biochemical improvement in diabetic neuropathy. Neuropharmacology. 2015 Oct;97:113-21.